Serologically H-Y antigen-negative XO mice.

J Immunogenet

Published: February 1985

In a series of six independent experiments organ homogenates of 35 mice of the XX, XO or XY sex chromosome constitutions were absorbed using three different anti-H-Y antisera raised in inbred female LEW rats. Residual activities of absorbed antisera were tested in the Raji cell, complement-dependent, cytotoxicity test. Homogenates of various tissues, including the gonads, of XX and XO females were equally unable to absorb H-Y antibodies, indicating that tissues of these mice do not carry the H-Y antigen. In contrast, XY male homogenates fully absorbed H-Y antibodies of antisera at concentrations of 1/2 to 1/4. We discuss our findings with special attention to the problem of the existence of one or more H-Y antigens and, to the genetic regulation of the expression of this antigen.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1744-313x.1985.tb00829.xDOI Listing

Publication Analysis

Top Keywords

h-y antibodies
8
serologically h-y
4
h-y antigen-negative
4
antigen-negative mice
4
mice series
4
series independent
4
independent experiments
4
experiments organ
4
organ homogenates
4
homogenates mice
4

Similar Publications

Introduction: Prasinezumab was shown to potentially delay motor progression in individuals with early-stage Parkinson's disease (PD) who were either treatment-naïve or on monoamine oxidase type B inhibitor (MAO-Bi) therapy in the PASADENA study. We report the rationale, design, and baseline patient characteristics of the PADOVA study, designed to evaluate prasinezumab in an early-stage PD population receiving standard-of-care (SOC) symptomatic medications.

Methods: PADOVA (NCT04777331) is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, in which individuals with early-stage PD on SOC stable symptomatic monotherapy (levodopa or MAO-Bi) receive intravenous prasinezumab 1500 mg every 4 weeks.

View Article and Find Full Text PDF

Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis.

Proc Natl Acad Sci U S A

December 2024

Department of Medicine, Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA 02115.

Article Synopsis
  • Fibrosis contributes to serious damage in organs, but treatments targeting specific activators have often failed, leading researchers to focus on the leukemia inhibitory factor receptor (LIFR) as a key player in fibrotic diseases like idiopathic pulmonary fibrosis (IPF).
  • In IPF, myofibroblasts highly express LIF, and fibroblasts in key fibrotic areas coexpress LIF and LIFR, demonstrating LIFR's role in amplifying signals from other fibrotic drivers like TGFβ1, IL-4, and IL-13.
  • Blocking LIFR reduces the activation of profibrotic genes and highlights LIFR's function as a master amplifier of harmful signals
View Article and Find Full Text PDF

Local CpG- siRNA treatment improves antitumor effects of immune checkpoint inhibitors.

Mol Ther Nucleic Acids

December 2024

Department of Immuno-Oncology, Beckman Research Institute, City of Hope Medical Center, Duarte, CA 91010, USA.

Immune checkpoint blockade (ICB) therapy has significantly benefited patients with several types of solid tumors and some lymphomas. However, many of the treated patients do not have a durable clinical response. It has been demonstrated that rescuing exhausted CD8 T cells is required for ICB-mediated antitumor effects.

View Article and Find Full Text PDF

Luspatercept has shown durable clinical efficacy for the treatment of anemia in transfusion-dependent patients with lower-risk myelodysplastic syndromes (LR-MDS). We report the results of a prespecified primary analysis of a phase 2 trial of luspatercept in non-transfusion-dependent (NTD) Japanese patients with anemia due to LR-MDS. Luspatercept (starting dose 1.

View Article and Find Full Text PDF

Alzheimer's disease is one of at least 26 diseases characterized by tau-positive accumulation in neurons, glia or both. However, it is still unclear what modifications cause soluble tau to transform into insoluble aggregates. We previously performed genetic screens that identified tyrosine kinase 2 (TYK2) as a candidate regulator of tau levels.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!